Abstract:Background: Enterovirus 71 (EV71), a member of the Enterovirus genus of the Picornaviridae family, is one of the causative pathogens of hand-foot-and-mouth disease (HFMD) and the most common etiological agent isolated from HFMD patients complicated with neurological disorders. EV71 has become an increasingly important neurotropic enterovirus in the post-poliomyelitis eradication era. Effective antiviral agents and vaccines against this virus are currently still under development. We reviewed publications on the development of EV71 vaccines in order to provide an overview of the field. Methods: Fifty-five articles on EV71 vaccine development, published from 1974 to 2009, were collected from Sun Yat-sen University library and reviewed. Results: Various types of vaccine have been developed for EV71. In results published to date, all vaccines for EV71 under development appear to elicit an immune response in rodents or in monkeys. According to the established regulatory standards, it may be relatively easy to acquire a license to use the inactivated virus in order to meet the immediate demands for EV71 control . With regard to the attenuated vaccine, it is critical to increase the genetic stability before clinical use, due to the risk of virulent revertants. The virus-like particle (VLP) vaccine, not only conserving the conformational epitopes, but also having no risk of virulent revertants, is another promising vaccine candidate for EV71, but needs further development. The VP1 capsid protein is the backbone antigen protein for developing subunit vaccine and epitope vaccine; these remain viable potential vaccine strategies worthy of further study and development. Conclusions: The conservation of the three-dimensional structure is important for the EV71 inactivated vaccine and VLP vaccine to induce a strong immune response. To develop EV71 vaccines with a high protection efficacy, strategies such as the use of adjuvant, strong promoters, tissue-specific promoters, and addition of mucosal immune adjuvant should be considered.

Process optimization for the rapid production of Enterovirus 71

Production of Enterovirus 71 in Vero Cells Grown on Microcarriers in a Bioreactor

Expression and purification of enterovirus type 71 polyprotein P1 using Pichia pastoris system

Efficient expression of enterovirus 71 based on virus-like particles vaccine

Development of culture procedure of enterovirus 71 in Vero cells with serum-free medium on microcarriers using a Cellspin cell cultivation system

The Bottlenecks of Preparing Virus Particles by Size Exclusion for Antibody Generation

Enterovirus71 Virus-Like Particles Produced from Insect Cells and Purified by Multistep Chromatography Elicit Strong Humoral Immune Responses in Mice

Efficient Production of Enterovirus 71 (EV71) Virus-like Particles by Controlling Promoter Strength in Insect Cells

Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris

Concentration and purification of enterovirus 71 using a weak anion-exchange monolithic column

Process Optimization for the Rapid Production of Adenoviral Vectors for Clinical Trials in a Disposable Bioreactor System.

Recovery Infectious Enterovirus 71 by Bac-to-Bac Expression System in vitro and in vivo

Expression and Immunogenicity of Novel Subunit Enterovirus 71 Vp1 Antigens

Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines.

Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial

Characterization of Human Enterovirus71 Virus-Like Particles Used for Vaccine Antigens

Enterovirus 71 vaccine: close but still far

Rational design of a DNA-launched live attenuated vaccine against human enterovirus 71

A safety study of inactivated Enterovirus 71 vaccine

Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor

Characterization of the Enterovirus 71 P1 Polyprotein Expressed Inpichia Pastoras a Candidate Vaccine